Baird Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $170 to $200.
June 21, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney has maintained an Outperform rating on Sarepta Therapeutics and increased the price target from $170 to $200.
The increase in the price target from $170 to $200 by a reputable analyst suggests a positive outlook for Sarepta Therapeutics, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100